

# EVIDENCE REVIEW GROUP

The Evidence Review Group (ERG) is an independent group brought together by ICER and composed of academic experts, patients, clinicians, epidemiologists, ethicists, and medical policy representatives of stakeholder groups including health plans and manufacturers.

The purpose of the ERG is to guide and help interpret the entire appraisal process. Members of the ERG are first convened to function as a “scoping committee” for the appraisal. During this phase the key questions for the appraisal are outlined, including elements such as the appropriate comparator technologies, patient outcomes of interest, patient subpopulations for which clinical and cost-effectiveness may vary systematically, time horizon for outcomes, and key aspects of the existing data that must be taken into account during the appraisal. The ERG may be divided into sub-committees that advise the ICER appraisal team at the mid-point of the appraisal on the early findings and challenges encountered. All of the ERG members listed below participated in scoping and/or mid-cycle activities, but not all were able to participate in the final ERG meeting.

At the final ERG meeting, members are asked to declare any interests in the technology or its comparator(s), or other potential influences on their expertise (listed below). The ERG meeting allows for in-depth deliberation on the findings of the ICER appraisal document and provides an opportunity for comment on the determination of the ICER integrated evidence rating. Although the ERG helps guide the final determination of the ICER Integrated Evidence Rating™, the final rating is ultimately a judgment made by ICER, and individual members of the ERG should not be viewed in any way as having endorsed this appraisal.

A list of all the participants in the Evidence Review Groups for the separate appraisals of radiation, surgery, and active surveillance is listed below; participant affiliations are listed as those in place at the time each appraisal was conducted.

Participants in ICER Prostate Cancer Evidence Review Groups	
Peter Albertsen, MD, MS Professor of Surgery, Chief and Program Director, Division of Urology University of Connecticut Health Center Director, Connecticut Institute for Clinical and Transitional Science	Jerry Avorn, MD Professor Medicine Harvard Medical School Chief, Pharmacoepidemiology and Pharmacoeconomics, Brigham & Women’s Hospital
John Ayanian, MD, MPP Professor of Medicine & Health Care Policy Harvard Medical School & Brigham & Women’s Hospital Professor of Health Policy & Management Harvard School of Public Health	Michael Barry, MD Professor of Medicine Harvard Medical School Chief, General Medicine, Massachusetts General Hospital

Marc Berger, MD Vice President, Global Health Outcomes Eli Lilly & Company	Wendy Everett, ScD President, New England Healthcare Institute
Peter Carroll, MD Professor and Chair, Department of Urology Ken and Donna Derr-Chevron Distinguished Professor University of California, San Francisco	Ted Ganiats, MD Chair, Department of Family & Preventive Medicine University of California at San Diego School of Medicine Executive Director, UCSD Health Services Research Center
Richard Choo, MD, FRCPC, FACR Associate Professor of Radiation Oncology Mayo Clinic College of Medicine	G. Scott Gazelle, MD, MPH, PhD Director, Institute for Technology Assessment, Massachusetts General Hospital Professor of Radiology, Harvard Medical School Professor of Health Policy & Management, Harvard School of Public Health
R. William Corwin, MD Medical Director, Medical Management and Policy Harvard Pilgrim Health Care	Marthe Gold, MD Professor & Chair, Community Health and Social Medicine City College of New York
Chris Covington, MBA (patient) Founder and Chairman Covington Associates	Lou Hochheiser, MD Medical Director, Clinical Policy Development Humana, Inc.
Myriam Curet, MD, FACS Professor, Department of Surgery Stanford University Chief Medical Officer, Intuitive Surgical	Jim C. Hu, MD, MPH Assistant Professor of Surgery, Harvard Medical School Director, Minimally Invasive Urologic Oncology Brigham & Women's Hospital
Kay Dickersin, PhD Professor and Director, Center for Clinical Trials, Department of Epidemiology Johns Hopkins School of Public Health	Nora Janjan, MD, MPSA, MBA Professor, Radiation Oncology and Symptom Research MD Anderson Cancer Center
Michele DiPalo Director, Health Services Evaluation Blue Cross & Blue Shield of Massachusetts	Jerome P. Kassirer, MD Distinguished Professor and Vice Chair Department of Medicine Tufts University School of Medicine

<p>Phil Kantoff, MD  Professor of Medicine, Harvard Medical School  Director, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute</p>	<p>Catherine Tak Piech, MBA  Vice President, Health Economics &amp; Outcomes Research  Centocor Ortho Biotech Services, LLC</p>
<p>Andre Konski, MD, MBA, MA  Chief Medical Officer  Fox Chase Cancer Center</p>	<p>Richard Platt, MD  Professor and Chair, Department of Ambulatory Care and Prevention  Harvard Medical School and Harvard Pilgrim Health Care</p>
<p>Armin Langenegger  Product Manager, Treatment Planning  Varian, Inc.</p>	<p>Lisa Prosser, PhD  Research Associate Professor, Child Health Evaluation and Research Unit, Department of Pediatrics and Communicable Diseases  University of Michigan</p>
<p>Terry Lindblom, MBA, PA-C (patient)  Clinical Advisor, Utilization Management &amp; Clinical Policy  Harvard Pilgrim Health Care</p>	<p>Alan B. Rosenberg, MD  Vice President, Medical Policy, Technology Assessment, and Credentialing Programs  Wellpoint, Inc.</p>
<p>Marcel Marc  Director of Oncology Systems  Varian, Inc.</p>	<p>James E. Sabin, MD  Director, Ethics Program  Harvard Pilgrim Health Care</p>
<p>Newell McElwee, PharmD, MSPH  Vice President, Evidence-Based Strategies  Pfizer, Inc.</p>	<p>Martin G. Sanda, MD  Associate Professor of Surgery, Harvard Medical School  Director, Prostate Cancer Care Center, Beth Israel Deaconess Medical Center</p>
<p>Robert E. Mechanic, MBA  Director, Health Industry Forum  Heller School of Social Policy and Management  Brandeis University</p>	<p>Manny Subramanian, PhD  Director of Research and Development  Best Medical, Inc.</p>
<p>David Most, PhD (patient)  Founder and President  Health Information Research, Inc.</p>	<p>William C. Taylor, MD  Associate Professor of Population Medicine,  Harvard Medical School</p>
<p>Lee Newcomer, MD  Senior Vice President, Oncology  UnitedHealthcare</p>	<p>Steven M. Teutsch, MD, MPH  Executive Director, US Outcomes Research  Merck &amp; Co., Inc.</p>

<p>Ian Thompson, MD  Professor and Chair, Department of Urology  University of Texas HSC at San Antonio</p>	<p>Milt Weinstein, PhD  Professor of Health Policy and Management  Harvard School of Public Health</p>
<p>Sean Tunis, MD, MSc  Founding Director  Center for Medical Technology Policy</p>	<p>Fiona Wilmot, MD, MPH  Medical Director of Policy, Pharmacy, and Therapeutics  Blue Shield of California</p>
<p>David Veroff, PhD  Vice President, Evaluation Services  Health Dialog</p>	<p>Anthony Zietman, MD, MB, BS  Professor of Radiation Oncology, Harvard Medical School  Associate Director, Harvard Radiation Oncology Residency Program, Massachusetts General Hospital</p>
<p>Bhadrasain Vikram, MD  Chief, Clinical Radiation Oncology  National Cancer Institute</p>	<p>Carmen Zullo  Nuclear Product Specialist  Siemens Medical Solutions</p>